Chardan lowered the firm’s price target on Alnylam (ALNY) to $425 from $475 and keeps a Buy rating on the shares post the Q4 report. The firm views Alnylam’s product revenue as the key driver for stock price appreciation in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
- Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating
- Alnylam Pharmaceuticals Projects Powerful Growth After Breakout Year
- Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating
- Alnylam price target lowered to $444 from $508 at Stifel